In October 2012 we announced that observations from the CUV102 study of SCENESSE® (afamelanotide 16mg implant) in vitiligo were e-published in the journal Archives of Dermatology. Earlier this month the article was fully published in the re-named JAMA Dermatology, with case study images from CUV102 featured on the cover. You can access the abstract to this article at the JAMA's website.
Grimes PE, et al (2013). "The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo" JAMA Dermatol. 149(1):68-73.